Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTRF71)

• Drug Name: BIIB 028 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMTRF71

Molecule-Related Drug Atlas

Drug(s) Targeting Heat shock protein 90 alpha (HSP90A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cromoglicate	DM74LZK	Asthma	CA23	Approved	[3]
Amlexanox	DM0DQM5	Respiratory tract inflammation	CA07	Approved	[3]
NVP-AUY922	DMTYXQF	Multiple myeloma	2A83	Phase 2	[4]
BIIB-021	DMPAJ41	Breast cancer	2C60-2C65	Phase 2	[5]
KW-2478	DMJGL72	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
VER 50589	DMFLZPC	Breast cancer	2C60-2C65	Phase 2	[4]
Tanespimycin	DMNLQHK	Breast cancer	2C60-2C65	Phase 2	[7]
Efungumab	DMBHP56	Breast cancer	2C60-2C65	Phase 2	[8]
SNX-5422	DMIU0VP	Haematological malignancy	2B33.Y	Phase 1/2	[9]
PU3	DMJO0BP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Heat shock protein 90 alpha (HSP90A)	TT78R5H	HS90A_HUMAN	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020039)
• [2] Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 1;19(17):4824-31.
• [3] Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
• [4] Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
• [5] BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9.
• [6] Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68.
• [7] Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8.
• [8] Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23.
• [9] SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55.